EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression

被引:4
|
作者
Ling, Wen [1 ]
Johnson, Sarah K. [1 ]
Mehdi, Syed J. [1 ]
Alapat, Daisy, V [1 ]
Bauer, Michael [1 ]
Zangari, Maurizio [1 ]
Schinke, Carolina [1 ]
Thanendrarajan, Sharmilan [1 ]
van Rhee, Frits [1 ]
Yaccoby, Shmuel [1 ]
机构
[1] Univ Arkansas Med Sci, Winthrop P Rockefeller Canc Inst, Myeloma Ctr, Dept Internal Med, Little Rock, AR 72205 USA
关键词
myeloma; pericytes; angiogenesis; mesenchymal cells; microenvironment; RISK MULTIPLE-MYELOMA; TUMOR-GROWTH; GAMMOPATHY; THERAPY; GENES; MGUS;
D O I
10.3390/cancers15184519
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary In multiple myeloma, malignant plasma cells accumulate in the bone marrow. The symptoms and complications include osteolytic bone disease, anemia, reduced kidney function, immunosuppression, and induction of tumor-associated angiogenesis. Mesenchymal cells are important components of bone marrow niches; studying their dysfunctional activities reveals key features in myeloma pathogenies and improves therapies. We discovered that a subset of mesenchymal cells that express the receptor EDNRA are more prevalent in bone marrow areas infiltrated with tumor cells. In normal conditions, these cells are attached to blood vessels and mediate their functions; but in myeloma they seem to detach and accumulate in the interstitial marrow. The proportion of EDNRA-expressing cells and the expression of EDNRA in bone biopsies is low in premalignant stages and highest in high-risk myeloma patients. EDNRA could serve as a useful novel clinical biomarker of disease progression and dysfunctional bone marrow vasculature.Abstract Multiple myeloma (MM) induces dysfunctional bone marrow (BM) mesenchymal cells and neoangiogenesis. Pericytes and smooth muscle cells (SMCs) could detach from vessels and become cancer-associated fibroblasts. We found that the pericyte and SMC marker endothelin receptor type A (EDNRA) is overexpressed in whole MM bone biopsies; we sought to characterize its expression. EDNRA expression gradually increased with disease progression. High-risk MM patients had higher EDNRA expression than low-risk MM patients and EDNRA expression was highest in focal lesions. High EDNRA expression was associated with high expression of pericyte markers (e.g., RGS5, POSTN, and CD146) and the angiogenic marker FLT1. A single-cell analysis of unexpanded BM mesenchymal cells detected EDNRA expression in a subset of cells that coexpressed mesenchymal cell markers and had higher expression of proliferation genes. Immunohistochemistry revealed that the number of EDNRA+ cells in the interstitial BM increased as MM progressed; EDNRA+ cells were prevalent in areas near the MM focal growth. EDNRA+ cells were detached from CD34+ angiogenic cells and coexpressed RGS5 and periostin. Therefore, they likely originated from pericytes or SMCs. These findings identify a novel microenvironmental biomarker in MM and suggest that the presence of detached EDNRA+ cells indicates disrupted vasculature and increased angiogenesis.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: Impact on disease progression
    Garcia-Sanchez, Daniel
    Gonzalez-Gonzalez, Alberto
    Alfonso-Fernandez, Ana
    Dujo-Gutierrez, Monica Del
    Perez-Campo, Flor M.
    WORLD JOURNAL OF STEM CELLS, 2023, 15 (05): : 421 - 437
  • [2] Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease
    Garcia-Gomez, Antonio
    De Las Rivas, Javier
    Ocio, Enrique M.
    Diaz-Rodriguez, Elena
    Montero, Juan C.
    Martin, Montserrat
    Blanco, Juan F.
    Sanchez-Guijo, Fermin M.
    Pandiella, Atanasio
    Miguel, Jesus F. San
    Garayoa, Mercedes
    ONCOTARGET, 2014, 5 (18) : 8284 - 8305
  • [3] Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression
    Maiso, Patricia
    Mogollon, Pedro
    Ocio, Enrique M.
    Garayoa, Mercedes
    CANCERS, 2021, 13 (11)
  • [4] Clinical Use of Bone Marrow, Bone Marrow Concentrate, and Expanded Bone Marrow Mesenchymal Stem Cells in Cartilage Disease
    Veronesi, Francesca
    Giavaresi, Gianluca
    Tschon, Matilde
    Borsari, Veronica
    Aldini, Nicolo Nicoli
    Fini, Milena
    STEM CELLS AND DEVELOPMENT, 2013, 22 (02) : 181 - 192
  • [5] Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients
    Wallace, SR
    Oken, MM
    Lunetta, KL
    Panoskaitsis-Mortari, A
    Masellis, AM
    CANCER, 2001, 91 (07) : 1219 - 1230
  • [6] Bone marrow mesenchymal stem cells are abnormal in multiple myeloma
    Corre, J.
    Mahtouk, K.
    Attal, M.
    Gadelorge, M.
    Huynh, A.
    Fleury-Cappellesso, S.
    Danho, C.
    Laharrague, P.
    Klein, B.
    Reme, T.
    Bourin, P.
    LEUKEMIA, 2007, 21 (05) : 1079 - 1088
  • [7] Bone marrow mesenchymal stem cells are abnormal in multiple myeloma
    J Corre
    K Mahtouk
    M Attal
    M Gadelorge
    A Huynh
    S Fleury-Cappellesso
    C Danho
    P Laharrague
    B Klein
    T Rème
    P Bourin
    Leukemia, 2007, 21 : 1079 - 1088
  • [8] Bone marrow myeloid cells in regulation of multiple myeloma progression
    Herlihy, Sarah E.
    Lin, Cindy
    Nefedova, Yulia
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (08) : 1007 - 1014
  • [9] Bone marrow myeloid cells in regulation of multiple myeloma progression
    Sarah E. Herlihy
    Cindy Lin
    Yulia Nefedova
    Cancer Immunology, Immunotherapy, 2017, 66 : 1007 - 1014
  • [10] Myeloma bone disease: A vicious cycle by interactions between myeloma cells and bone marrow cells
    Matsumoto, T.
    Abe, M.
    CANCER TREATMENT REVIEWS, 2006, 32 : S23 - S23